182 related articles for article (PubMed ID: 20481176)
21. Utilisation pattern of fentanyl transdermal system in The Netherlands.
Breekveldt-Postma NS; Penning-van Beest FJ; Herings RM
Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):129-34. PubMed ID: 15386723
[TBL] [Abstract][Full Text] [Related]
22. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
23. Characterization of early versus late opioid iatrogenic withdrawal syndrome in critically ill children transitioning from fentanyl -infusions to methadone.
Hintze TD; Miller JL; Neely SB; Lim SY; Gupta N; Johnson PN
J Opioid Manag; 2023; 19(1):43-56. PubMed ID: 36683300
[TBL] [Abstract][Full Text] [Related]
24. [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Leppert W; Luczak J; Gorzelińska L; Kozikowska J
Przegl Lek; 2000; 57(1):59-64. PubMed ID: 10907375
[TBL] [Abstract][Full Text] [Related]
25. Continuous intravenous analgesia with fentanyl or morphine after gynecological surgery: a cohort study.
Russo A; Grieco DL; Bevilacqua F; Anzellotti GM; Scarano A; Scambia G; Costantini B; Marana E
J Anesth; 2017 Feb; 31(1):51-57. PubMed ID: 27743121
[TBL] [Abstract][Full Text] [Related]
26. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
27. Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: A systematic review of clinical studies.
Duceppe MA; Perreault MM; Frenette AJ; Burry LD; Rico P; Lavoie A; Gélinas C; Mehta S; Dagenais M; Williamson DR
J Clin Pharm Ther; 2019 Apr; 44(2):148-156. PubMed ID: 30569508
[TBL] [Abstract][Full Text] [Related]
28. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT).
Tsutsumi Y; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
Pain Med; 2006; 7(2):164-5. PubMed ID: 16634729
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
30. Disaster after the plaster. Fentanyl withdrawal symptoms in a curable hospice patient.
Maathuis MH; Dijkstra DD
Eur J Gen Pract; 2011 Dec; 17(4):229-32. PubMed ID: 21877907
[TBL] [Abstract][Full Text] [Related]
31. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
32. Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Garbe E; Jobski K; Schmid U
Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):191-8. PubMed ID: 21681850
[TBL] [Abstract][Full Text] [Related]
33. Withdrawal syndrome in the pediatric intensive care unit. Incidence and risk factors.
Fernández-Carrión F; Gaboli M; González-Celador R; Gómez de Quero-Masía P; Fernández-de Miguel S; Murga-Herrera V; Serrano-Ayestarán O; Sánchez-Granados JM; Payo-Pérez R
Med Intensiva; 2013 Mar; 37(2):67-74. PubMed ID: 22608303
[TBL] [Abstract][Full Text] [Related]
34. Long-term observations of patients receiving transdermal fentanyl after a randomized trial.
Nugent M; Davis C; Brooks D; Ahmedzai SH
J Pain Symptom Manage; 2001 May; 21(5):385-91. PubMed ID: 11369159
[TBL] [Abstract][Full Text] [Related]
35. Opioid and benzodiazepine withdrawal symptoms in paediatric intensive care patients.
Franck LS; Naughton I; Winter I
Intensive Crit Care Nurs; 2004 Dec; 20(6):344-51. PubMed ID: 15567675
[TBL] [Abstract][Full Text] [Related]
36. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
[TBL] [Abstract][Full Text] [Related]
37. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
Otis J; Rothman M
Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous administration of fentanyl and midazolam to prevent withdrawal after prolonged sedation in children.
Tobias JD
Crit Care Med; 1999 Oct; 27(10):2262-5. PubMed ID: 10548218
[TBL] [Abstract][Full Text] [Related]
39. Clinical problems with transdermal fentanyl titration from 25 to 50 microg/hr.
Mercadante S; Villari P; Ferrera P
J Pain Symptom Manage; 2001 Jun; 21(6):448-9. PubMed ID: 11417535
[No Abstract] [Full Text] [Related]
40. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
